Pfizer Expands HYMPAVZI Approval to Hemophilia Patients with Inhibitors in Europe
Event summary
- European Commission approves expanded indication for HYMPAVZI to treat hemophilia A or B patients with inhibitors aged 12+.
- Phase 3 BASIS trial shows 93% reduction in mean treated annualized bleeding rate compared to on-demand therapy.
- HYMPAVZI offers once-weekly subcutaneous administration without routine lab monitoring.
- FDA review for expanded U.S. indication pending with PDUFA action date in Q2 2026.
The big picture
This approval addresses a critical unmet need for hemophilia patients with inhibitors, who face limited treatment options due to neutralizing antibodies. HYMPAVZI's unique mechanism targeting TFPI differentiates it from traditional factor replacement therapies, potentially reshaping the hemophilia treatment landscape. Pfizer's long-standing commitment to hemophilia care is reinforced by this strategic expansion of HYMPAVZI's indications.
What we're watching
- Regulatory Momentum
- Whether the FDA approval process will follow the EC's lead and expand HYMPAVZI's U.S. indication.
- Market Penetration
- The pace at which Pfizer can commercialize HYMPAVZI for inhibitor patients across Europe.
- Competitive Dynamics
- How this approval affects Pfizer's positioning against competitors in the hemophilia treatment space.
Related topics